Pamela Kunz, MD, discusses the importance of tailoring treatments to individual patients with neuroendocrine tumors.
Pamela L. Kunz
Advertisement
Articles by Pamela L. Kunz
Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses the impact of the approval of lanreotide.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
5